See more : TDC SOFT Inc. (4687.T) Income Statement Analysis – Financial Results
Complete financial analysis of Zoetis Inc. (ZOE.DE) income statement, including revenue, profit margins, EPS and key performance metrics. Get detailed insights into the financial performance of Zoetis Inc., a leading company in the Drug Manufacturers – Specialty & Generic industry within the Healthcare sector.
- China Evergrande New Energy Vehicle Group Limited (EVGRF) Income Statement Analysis – Financial Results
- Norse Atlantic ASA (NORSE.OL) Income Statement Analysis – Financial Results
- PT Medikaloka Hermina Tbk (HEAL.JK) Income Statement Analysis – Financial Results
- Helium Evolution Incorporated (HEEVF) Income Statement Analysis – Financial Results
- ENM Holdings Limited (ENMHF) Income Statement Analysis – Financial Results
Zoetis Inc. (ZOE.DE)
About Zoetis Inc.
Zoetis Inc. discovers, develops, manufactures, and commercializes animal health medicines, vaccines, and diagnostic products in the United States and internationally. It commercializes products primarily across species, including livestock, such as cattle, swine, poultry, fish, and sheep; and companion animals comprising dogs, cats, and horses. The company also offers vaccines, which are biological preparations to prevent diseases of the respiratory, gastrointestinal, and reproductive tracts or induce a specific immune response; anti-infectives that prevent, kill, or slow the growth of bacteria, fungi, or protozoa; and parasiticides that prevent or eliminate external and internal parasites, which include fleas, ticks, and worms. It also provides other pharmaceutical products that comprise pain and sedation, antiemetic, reproductive, and oncology products; dermatology products for itch associated with allergic conditions and atopic dermatitis; and medicated feed additives, which offer medicines to livestock. In addition, the company provides portable blood and urine analysis testing, including point-of-care diagnostic products, instruments and reagents, rapid immunoassay tests, reference laboratory kits and services, and blood glucose monitors; and other non-pharmaceutical products, including nutritionals and agribusiness services, as well as products and services in areas, such as biodevices, genetics tests, and precision animal health. It markets its products to veterinarians, livestock producers, and retail outlets, as well as third-party veterinary distributors through its sales representatives, and technical and veterinary operations specialists. The company was founded in 1952 and is headquartered in Parsippany, New Jersey.
| Metric | 2023 | 2022 | 2021 | 2020 | 2019 | 2018 | 2017 | 2016 | 2015 | 2014 | 2013 | 2012 | 2011 | 2010 | 2009 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Revenue | 8.54B | 8.08B | 7.78B | 6.68B | 6.26B | 5.83B | 5.31B | 4.89B | 4.77B | 4.79B | 4.56B | 4.34B | 4.23B | 3.58B | 2.76B |
| Cost of Revenue | 2.56B | 2.45B | 2.30B | 2.06B | 1.99B | 1.91B | 1.78B | 1.67B | 1.74B | 1.72B | 1.67B | 1.56B | 1.65B | 1.44B | 1.08B |
| Gross Profit | 5.98B | 5.63B | 5.47B | 4.62B | 4.27B | 3.91B | 3.53B | 3.22B | 3.03B | 3.07B | 2.89B | 2.77B | 2.58B | 2.14B | 1.68B |
| Gross Profit Ratio | 70.03% | 69.63% | 70.38% | 69.18% | 68.18% | 67.19% | 66.55% | 65.92% | 63.53% | 64.12% | 63.41% | 63.95% | 60.97% | 59.69% | 60.94% |
| Research & Development | 614.00M | 539.00M | 508.00M | 463.00M | 457.00M | 432.00M | 382.00M | 376.00M | 364.00M | 396.00M | 399.00M | 409.00M | 427.00M | 411.00M | 368.00M |
| General & Administrative | 1.87B | 1.72B | 1.71B | 1.49B | 1.47B | 1.48B | 1.33B | 1.36B | 1.53B | 1.64B | 1.61B | 1.47B | 1.45B | 1.38B | 1.07B |
| Selling & Marketing | 281.00M | 287.00M | 292.00M | 233.00M | 167.00M | 158.00M | 154.00M | 119.00M | 106.00M | 132.00M | 143.00M | 141.00M | 0.00 | 0.00 | 0.00 |
| SG&A | 2.15B | 2.01B | 2.00B | 1.73B | 1.64B | 1.48B | 1.33B | 1.36B | 1.53B | 1.64B | 1.61B | 1.47B | 1.45B | 1.38B | 1.07B |
| Other Expenses | 0.00 | 150.00M | 161.00M | 160.00M | 155.00M | 83.00M | -6.00M | 2.00M | -81.00M | -7.00M | 9.00M | 32.00M | 21.00M | 26.00M | 6.00M |
| Operating Expenses | 2.77B | 2.70B | 2.67B | 2.35B | 2.25B | 2.03B | 1.81B | 1.83B | 1.96B | 2.10B | 2.07B | 1.94B | 1.95B | 1.85B | 1.47B |
| Cost & Expenses | 5.32B | 5.15B | 4.97B | 4.41B | 4.24B | 3.94B | 3.58B | 3.49B | 3.70B | 3.82B | 3.74B | 3.51B | 3.60B | 3.30B | 2.55B |
| Interest Income | 105.00M | 50.00M | 6.00M | 12.00M | 37.00M | 31.00M | 13.00M | 8.00M | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
| Interest Expense | 239.00M | 221.00M | 224.00M | 231.00M | 223.00M | 206.00M | 175.00M | 166.00M | 124.00M | 117.00M | 113.00M | 31.00M | 36.00M | 37.00M | 26.00M |
| Depreciation & Amortization | 491.00M | 465.00M | 448.00M | 441.00M | 155.00M | 117.00M | 91.00M | 85.00M | 61.00M | 60.00M | 60.00M | 200.00M | 205.00M | 185.00M | 124.00M |
| EBITDA | 3.67B | 3.34B | 3.16B | 2.67B | 2.44B | 2.08B | 1.94B | 1.63B | 1.05B | 1.14B | 1.01B | 1.06B | 858.00M | 498.00M | 345.00M |
| EBITDA Ratio | 42.91% | 37.60% | 37.50% | 40.88% | 35.62% | 35.73% | 34.11% | 30.36% | 22.04% | 21.36% | 19.49% | 24.49% | 20.27% | 13.90% | 12.50% |
| Operating Income | 3.22B | 2.89B | 2.76B | 2.29B | 2.08B | 1.88B | 1.73B | 1.40B | 1.07B | 969.00M | 820.00M | 830.00M | 632.00M | 287.00M | 215.00M |
| Operating Income Ratio | 37.70% | 35.74% | 35.43% | 34.28% | 33.15% | 32.29% | 32.50% | 28.58% | 22.46% | 20.25% | 17.98% | 19.14% | 14.93% | 8.01% | 7.79% |
| Total Other Income/Expenses | -285.00M | -272.00M | -315.00M | -273.00M | -217.00M | -191.00M | -200.00M | -169.00M | -525.00M | -149.00M | -130.00M | -120.00M | -238.00M | -109.00M | -363.00M |
| Income Before Tax | 2.94B | 2.66B | 2.49B | 2.00B | 1.80B | 1.69B | 1.53B | 1.23B | 545.00M | 820.00M | 690.00M | 710.00M | 394.00M | 178.00M | -148.00M |
| Income Before Tax Ratio | 34.36% | 32.87% | 32.00% | 29.90% | 28.77% | 29.01% | 28.74% | 25.12% | 11.44% | 17.14% | 15.13% | 16.37% | 9.31% | 4.97% | -5.36% |
| Income Tax Expense | 596.00M | 545.00M | 454.00M | 360.00M | 301.00M | 266.00M | 663.00M | 409.00M | 206.00M | 233.00M | 187.00M | 274.00M | 146.00M | 67.00M | -47.00M |
| Net Income | 2.34B | 2.11B | 2.04B | 1.64B | 1.50B | 1.43B | 864.00M | 821.00M | 339.00M | 583.00M | 504.00M | 436.00M | 245.00M | 110.00M | -100.00M |
| Net Income Ratio | 27.43% | 26.16% | 26.20% | 24.54% | 23.96% | 24.52% | 16.28% | 16.80% | 7.11% | 12.18% | 11.05% | 10.06% | 5.79% | 3.07% | -3.62% |
| EPS | 5.07 | 4.51 | 4.29 | 3.44 | 3.14 | 2.96 | 1.76 | 1.66 | 0.68 | 1.16 | 1.01 | 0.87 | 0.51 | 0.23 | -0.21 |
| EPS Diluted | 5.07 | 4.49 | 4.27 | 3.42 | 3.11 | 2.93 | 1.75 | 1.65 | 0.68 | 1.16 | 1.01 | 0.87 | 0.51 | 0.23 | -0.21 |
| Weighted Avg Shares Out | 462.33M | 468.89M | 474.30M | 475.50M | 478.10M | 483.06M | 489.92M | 495.72M | 499.71M | 501.06M | 500.00M | 500.00M | 478.13M | 478.13M | 478.13M |
| Weighted Avg Shares Out (Dil) | 462.27M | 470.39M | 476.72M | 478.57M | 481.80M | 486.90M | 493.16M | 498.23M | 502.02M | 502.03M | 500.32M | 500.00M | 481.79M | 481.79M | 481.79M |
Source: https://incomestatements.info
Category: Stock Reports
How did Zoetis’ revenue grow in 2023 compared to 2022?
For full year 2023, the company reported revenue of $8.5 billion, an increase of 6% compared with full year 2022. On an operational basis, revenue for full year 2023 increased 7%, excluding the impact of foreign currency.
How did Zoetis’ adjusted net income change in 2023?
Net income for full year 2023 was $2.3 billion, or $5.07 per diluted share, an increase of 11% and 13%, respectively, on a reported basis. Adjusted net incomefor full year 2023 was $2.5 billion, or $5.32 per diluted share, an increase of 7% and 9%, respectively, on a reported and operational basis.
What were the key financial highlights of Zoetis’ Q4 2023?
Delivers 8% Operational Growth in Revenue and 6% Operational Growth in Adjusted Net Income for Fourth Quarter 2023.
Reports Adjusted Net Income of $569 Million, or Adjusted Diluted EPS of $1.24, for Fourth Quarter 2023.
What drove Zoetis’ operational revenue growth in 2023?
Companion animal revenue grew 8% operationally1 for 2023, led by our monoclonal antibodies for OA pain, LibrelaTM and Solensia®, growth in our key dermatology portfolio and Simparica Trio®. Revenue for our livestock portfolio grew 6% operationally1 for 2023, with growth driven equally by price and volume.